 |
PDBsum entry 4f64
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transferase/transferase inhibitor
|
PDB id
|
|
|
|
4f64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase/transferase inhibitor
|
 |
|
Title:
|
 |
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with compound 6
|
|
Structure:
|
 |
Fibroblast growth factor receptor 1. Chain: a, b. Fragment: kinase domain (unp residues 458-765). Synonym: fgfr-1, basic fibroblast growth factor receptor 1, bfgfr, bfgf-r-1, fms-like tyrosine kinase 2, flt-2, n-sam, proto-oncogenE C- fgr. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: fgfr1, bfgfr, cek, fgfbr, flg, flt2, hbgfr. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
2.05Å
|
R-factor:
|
0.217
|
R-free:
|
0.269
|
|
|
Authors:
|
 |
R.A.Norman,J.Breed,D.Ogg
|
|
Key ref:
|
 |
R.A.Norman
et al.
(2012).
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
J Med Chem,
55,
5003-5012.
PubMed id:
|
 |
|
Date:
|
 |
|
14-May-12
|
Release date:
|
06-Jun-12
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P11362
(FGFR1_HUMAN) -
Fibroblast growth factor receptor 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
822 a.a.
278 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
J Med Chem
55:5003-5012
(2012)
|
|
PubMed id:
|
|
|
|
|
| |
|
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
|
|
R.A.Norman,
A.K.Schott,
D.M.Andrews,
J.Breed,
K.M.Foote,
A.P.Garner,
D.Ogg,
J.P.Orme,
J.H.Pink,
K.Roberts,
D.A.Rudge,
A.P.Thomas,
A.G.Leach.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |